Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Brain and Central Nervous System Tumors|Breast Cancer|Gastrointestinal Carcinoid Tumor|Islet Cell Tumor|Lung Cancer|Lymphoma|Melanoma (Skin)|Neoplastic Syndrome
Interventions: RADIATION: yttrium Y 90-edotreotide
Sponsor: Novartis Pharmaceuticals